Now this is going to be extremely interesting. Melky Cabrera spent two-thirds of the 2012 season as one of the NL’s 10-best players. Although he’s going to miss the final 46 games after testing positive for enhanced testosterone levels, he has a decent chance of winning the batting title given his current .346 average, with only Andrew McCutchen ahead of him at .359.
Cabrera was also plenty good with the Royals last season, hitting .305/.339/.470 with 18 homers, 87 RBI and 20 steals. That’s not at the level of this year’s .346/.390/.516 line, but it probably would have gotten a three-year contract worth $7 million-$8 million per year had he been a free agent then. Instead, he had to wait one more year.
Now Cabrera will head into free agency with All-Star numbers and a tarnished reputation. If the Giants make the playoffs and Cabrera shows early-season form in October, it could do wonders for his value. However, if the Giants miss the playoffs — as seems quite likely — then there’s nothing Cabrera can do between now and the winter to enhance his value. He wouldn’t even be able to play winter ball given his status as a suspended MLB player.
My thinking was that Cabrera was looking at something like $40 million-$48 million for four years as a free agent this winter. After all, he’s just 28 years old, making him something of a rarity — few quality position players hit free agency prior to turning 30. He’s not really being looked at as a center fielder any longer, but that was OK. There were other center fielders available anyway (Michael Bourn, B.J, Upton, Shane Victorino), and there will be more contenders looking for help in the corners than in center. Given his youth and his recent play, $10 million-$12 million per year seemed pretty reasonable.
Now there’s no way he’s getting that kind of contract. I imagine he’ll need to a take a one-year, make-good contract and then head back into free agency. He’ll still do well enough salary-wise — someone will risk $8 million-$10 million on him — but he’ll need to prove himself all over again in order to get a long-term contract.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.